Q1 EPS Forecast for Theravance Biopharma Cut by Analyst

Theravance Biopharma, Inc. (NASDAQ:TBPH) – Research analysts at Zacks Research lowered their Q1 2025 earnings per share estimates for shares of Theravance Biopharma in a research report issued to clients and investors on Wednesday, March 19th. Zacks Research analyst R. Department now expects that the biopharmaceutical company will post earnings per share of ($0.43) for the quarter, down from their prior estimate of ($0.36). The consensus estimate for Theravance Biopharma’s current full-year earnings is ($1.09) per share. Zacks Research also issued estimates for Theravance Biopharma’s Q2 2025 earnings at ($0.41) EPS, Q3 2025 earnings at ($0.29) EPS, Q1 2026 earnings at ($0.50) EPS, Q2 2026 earnings at ($0.50) EPS, Q3 2026 earnings at ($0.33) EPS, Q4 2026 earnings at $0.19 EPS, FY2026 earnings at ($1.13) EPS and FY2027 earnings at ($0.96) EPS.

Separately, HC Wainwright reissued a “buy” rating and set a $15.00 price target on shares of Theravance Biopharma in a report on Tuesday, February 25th. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $13.75.

Theravance Biopharma Stock Performance

Shares of Theravance Biopharma stock opened at $9.39 on Monday. The company has a market cap of $464.53 million, a P/E ratio of -9.30 and a beta of 0.15. The firm has a fifty day moving average of $9.34 and a two-hundred day moving average of $9.07. Theravance Biopharma has a one year low of $7.44 and a one year high of $10.90.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.26). The company had revenue of $18.75 million for the quarter, compared to analyst estimates of $29.90 million. Theravance Biopharma had a negative return on equity of 24.79% and a negative net margin of 78.18%.

Institutional Trading of Theravance Biopharma

Institutional investors have recently added to or reduced their stakes in the stock. Aquatic Capital Management LLC acquired a new stake in shares of Theravance Biopharma during the 4th quarter valued at approximately $25,000. Quantbot Technologies LP purchased a new position in Theravance Biopharma in the 3rd quarter valued at approximately $60,000. KLP Kapitalforvaltning AS acquired a new position in Theravance Biopharma during the fourth quarter worth $69,000. Teacher Retirement System of Texas purchased a new stake in Theravance Biopharma during the fourth quarter worth $103,000. Finally, ClearAlpha Technologies LP acquired a new stake in Theravance Biopharma in the 4th quarter valued at about $109,000. Hedge funds and other institutional investors own 99.10% of the company’s stock.

Insider Buying and Selling at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 4,000 shares of the stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $9.00, for a total value of $36,000.00. Following the completion of the transaction, the senior vice president now owns 309,565 shares in the company, valued at $2,786,085. This trade represents a 1.28 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 6.90% of the stock is owned by corporate insiders.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.